Sunrest Life Science Limited is an Indian healthcare enterprise that has transitioned from a pure-play marketing firm into an integrated pharmaceutical entity. Listed on the **NSE Emerge Platform** on **November 20, 2023**, the company is currently executing a multi-pronged strategy of backward integration, capital restructuring, and portfolio diversification within the Indian pharmaceutical landscape—an industry that contributes **1.72% to India’s GDP** and ranks **3rd globally by volume**. --- ### Hybrid Operational Model: From Asset-Light to Integrated Manufacturing Sunrest historically operated under a strictly asset-light business model, focusing on the marketing and trading of healthcare products, medicines, and cosmetics. Under this model, products are manufactured by third parties and sold under the proprietary **Sunrest** brand. However, the company has recently shifted toward a hybrid model through strategic backward integration: * **Core Parent Activity:** Trading and marketing of pharmaceutical formulations. * **Manufacturing Integration:** On **March 29, 2025**, Sunrest acquired a **51.49%** controlling stake in **Hetvi Lifesciences Private Limited (HLPL)**. * **Subsidiary Role:** Unlike the parent, HLPL is directly engaged in the **manufacture of healthcare products**, providing Sunrest with in-house production capabilities and technical synergies. **Subsidiary Performance Overview (FY25)** | Entity | Nature of Business | Ownership | Turnover | | :--- | :--- | :--- | :--- | | **Sunrest Life Science Ltd** | Trading & Marketing | Parent | - | | **Hetvi Lifesciences Pvt Ltd** | Manufacturing | **51.49%** | **₹33.41 Crore** | --- ### Strategic Growth Initiatives & Capital Infusion The company is currently in a high-growth phase, utilizing inorganic expansion and equity raises to scale operations. #### 1. The 2026 Rights Issue To fund long-term value creation and support its expanding balance sheet, Sunrest has announced a significant **Rights Issue**: * **Total Issue Size:** Up to **₹15.10 Crores**. * **Rights Entitlement Ratio:** **1:1** (One new share for every one share held). * **Face Value:** **₹10/-** per share. * **Record Date:** **March 23, 2026**. * **Issue Period:** **April 02, 2026**, to **April 30, 2026**. * **Terms:** Full amount payable at the time of application. #### 2. Inorganic Expansion & Debt Conversion The acquisition of **Hetvi Lifesciences** was executed through a strategic debt-to-equity conversion in **March 2025**. Sunrest converted outstanding loans into **2,123,000 equity shares** of HLPL at **₹26 per share**, totaling a **₹5.52 Crore** investment. This move optimized operational synergies and integrated a specialized professional team into the group. --- ### Capital Structure & Financial Health Sunrest maintains a stable capital structure following its **₹10.85 Crore IPO**, which involved the issuance of **12,91,200 shares** at a premium of **₹74** per share. **Share Capital Summary (as of March 31, 2025)** * **Authorized Share Capital:** **₹14,00,00,000** * **Paid-up Share Capital:** **₹4,29,12,000** #### Debt Profile & Asset Management The company utilizes a tiered financing strategy involving institutional debt and director-backed support: * **Institutional Term Loans:** Includes a **9.5%** floating rate loan from **ICICI Bank** for immovable property (Office 608, Ahmedabad) and vehicle loans from **Indian Overseas Bank (7.30%)** and **Kalupur Commercial Co-op Bank (8.30%)**. * **Subsidiary Financing:** **SIDBI** provides financing secured by HLPL property and director guarantees. * **Related Party Loans:** Historically, the company relied on **interest-free unsecured loans** from directors. Notably, balances from **Amit Thakkar** and **Bharat Thakkar** (totaling over **₹2.67 Crore** in 2024) were reduced to nominal or zero amounts by **March 2025**, indicating a strengthening of the independent balance sheet. * **Asset Integrity:** Physical verification of inventory and **Property, Plant, and Equipment (PPE)** is conducted regularly. No material discrepancies exceeding **10%** have been reported. Original title deeds for immovable properties are currently **mortgaged** to secure financing. --- ### Market Positioning & Future Therapeutic Focus Sunrest is aligning its product pipeline with the **'Atmanirbhar Bharat'** vision and the **Production Linked Incentive (PLI)** schemes to capitalize on India's role as the "pharmacy of the world." **Targeted Growth Segments:** * **High-Demand Generics:** Leveraging India's **80% global share** in antiretroviral drugs and low-cost vaccines. * **Specialty Medicines:** Expansion into **Oncology, Immunology**, and treatments for chronic/rare conditions. * **Biotechnology:** Investing in **Biosimilars** and R&D to move up the value chain. * **Global Hub Advantage:** Positioning to support the **40% of US generic demand** and **25% of UK medicine supply** sourced from India. --- ### Risk Assessment & Governance Challenges Investors should monitor several regulatory and macroeconomic headwinds that could impact performance. #### 1. Regulatory & Compliance Hurdles The company has faced recent challenges regarding statutory governance: * **LODR Non-Compliance:** Sunrest failed to fill the **Company Secretary & Compliance Officer** vacancy within the mandated **3-month** window (Regulation 6(1A)) following a resignation in **December 2024**. The position remained vacant until **March 24, 2025**. * **Exchange Penalties:** The company incurred **revocation fees** paid to the Stock Exchange due to delayed filings. * **Accounting Standards:** The company has **not yet made provisions** for employee retirement benefits as required under **AS-15**. #### 2. Macroeconomic & Operational Risks * **Pricing & Margins:** Global **monetary tightening** has increased financing costs. Simultaneously, reimbursement constraints in the **US, Eurozone, and Japan** are creating downward pricing pressure on pharma exports. * **Human Capital:** Difficulty in sourcing KMPs suggests a potential risk in **succession planning** and talent acquisition. * **Liquidity:** While the company can meet liabilities due within **1 year**, auditors note there is no long-term guarantee of viability, and inflation-sensitive markets continue to squeeze operational margins. | Risk Factor | Impact Level | Mitigation/Status | | :--- | :--- | :--- | | **Litigation** | Low | **No pending litigations** affecting financial position. | | **Contractual** | Low | No foreseeable losses in long-term or derivative contracts. | | **Statutory Dues** | Low | Timely transfers to the **Investor Education and Protection Fund**. | | **Financing** | Moderate | Transitioning from director loans to institutional/equity funding. |